stimulant use disorder | CARLAT PUBLISHING

Expert Q&A

Contingency Management for Stimulant Use Disorder

October 1, 2024

Dominick DePhilippis, PhD

Deputy National Mental Health Director, Substance Use Disorders, Office of Mental Health, Veterans Health Administration, Department of Veterans Affairs.

Dr. DePhilippis has no financial relationships with companies related to this material.

Contingency management (CM) is a clinical approach that leverages principles of operant conditioning to treat stimulant use disorder. In this interview, Dr. DePhilippis explains how CM incentivizes recovery behaviors like abstinence with immediate rewards, making it an effective treatment tool. Learn how this evidence-based strategy works, why it’s considered the gold standard for treating stimulant use disorder, and the challenges of implementing CM in real-world settings.

Expert Q&A

Update on Stimulant Use Disorder

October 1, 2024

Brian Hurley, MD, MBA, FAPA, DFASAM

Brian Hurley, MD, MBA, FAPA, DFASAM

Addiction physician; President of the American Society for Addiction Medicine; Medical Director of the Bureau of Substance Abuse Prevention and Control, Los Angeles County Department of Public Health, Los Angeles, CA.

Dr. Hurley has no financial relationships with companies related to this material.

The interview with Dr. Hurley provides crucial insights into the world of psychostimulants, their misuse, and the emerging Fourth Wave of the Overdose Epidemic. Dr. Hurley discusses everything from the differences between stimulants like methamphetamine and cocaine to the importance of harm reduction strategies and evidence-based treatments for stimulant use disorder.

Clinical Update

Overview of Stimulants

October 1, 2024

Michael Weaver, MD, FASAM and Noah Capurso, MD

Michael Weaver, MD, DFASAM. Professor and Medical Director, Center for Neurobehavioral Research on Addiction at the University of Texas Medical School, Houston, TX.

Noah Capurso, MD, MHS. Associate Professor of Psychiatry, Yale University, and Editor-in-Chief, The Carlat Addiction Treatment Report.

Drs. Weaver and Capurso have no financial relationships with companies related to this material.

This article offers an insightful overview of the pharmacology of various stimulant drugs, their potential for misuse, and the dangers they pose—especially with rising overdose rates due to contamination with fentanyl. Learn about the history, various classes of stimulants, and the treatments available for stimulant use disorder, as well as the crucial harm reduction strategies aimed at minimizing risks.

Contingency Management with Dr. Dominick DePhilippis

June 3, 2024

Noah Capurso, MD

In today's episode, Dr. DePhilippis tells us all about Contingency Management: what it is, how it works, and its evidence for the treatment of stimulant use disorders.

Clinical Update

Naltrexone: A Jack of All Trades?

April 1, 2023

Julio Cesar Nunes, MD

Julio Cesar Nunes, MD. Psychiatry resident, Yale University. New Haven, CT.

Noah Capurso, MD, MHS. Assistant professor of psychiatry, Yale University. New Haven, CT. Editor-in-chief of The Carlat Addiction Treatment Report.

Dr. Nunes and Dr. Capurso have no financial relationships with companies related to this material.

Naltrexone was once hailed as a treatment for all addictive disorders. While the hype has not entirely panned out, it still holds an important place in our armamentarium of addiction treatments. Here, we review the evidence for its use and provide prescribing recommendations.